469 related articles for article (PubMed ID: 36835116)
1. Therapeutic Implications of the Drug Resistance Conferred by Extracellular Vesicles Derived from Triple-Negative Breast Cancer Cells.
Yi YW
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835116
[TBL] [Abstract][Full Text] [Related]
2. Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells.
Ozawa PMM; Alkhilaiwi F; Cavalli IJ; Malheiros D; de Souza Fonseca Ribeiro EM; Cavalli LR
Breast Cancer Res Treat; 2018 Dec; 172(3):713-723. PubMed ID: 30173296
[TBL] [Abstract][Full Text] [Related]
3. Macrophage-Derived Extracellular Vesicles as Drug Delivery Systems for Triple Negative Breast Cancer (TNBC) Therapy.
Haney MJ; Zhao Y; Jin YS; Li SM; Bago JR; Klyachko NL; Kabanov AV; Batrakova EV
J Neuroimmune Pharmacol; 2020 Sep; 15(3):487-500. PubMed ID: 31722094
[TBL] [Abstract][Full Text] [Related]
4. Serum-derived extracellular vesicles from breast cancer patients contribute to differential regulation of T-cell-mediated immune-escape mechanisms in breast cancer subtypes.
Graham R; Gazinska P; Zhang B; Khiabany A; Sinha S; Alaguthurai T; Flores-Borja F; Vicencio J; Beuron F; Roxanis I; Matkowski R; Liam-Or R; Tutt A; Ng T; Al-Jamal KT; Zhou Y; Irshad S
Front Immunol; 2023; 14():1204224. PubMed ID: 37441083
[TBL] [Abstract][Full Text] [Related]
5. Extracellular Vesicles in Chemoresistance.
De Rubis G; Bebawy M
Subcell Biochem; 2021; 97():211-245. PubMed ID: 33779919
[TBL] [Abstract][Full Text] [Related]
6. Circulating extracellular vesicles from patients with breast cancer enhance migration and invasion via a Src‑dependent pathway in MDA‑MB‑231 breast cancer cells.
Ramírez-Ricardo J; Leal-Orta E; Martínez-Baeza E; Ortiz-Mendoza C; Breton-Mora F; Herrera-Torres A; Elizalde-Acosta I; Cortes-Reynosa P; Thompson-Bonilla R; Perez Salazar E
Mol Med Rep; 2020 Sep; 22(3):1932-1948. PubMed ID: 32582965
[TBL] [Abstract][Full Text] [Related]
7. The roles of extracellular vesicles in gastric cancer development, microenvironment, anti-cancer drug resistance, and therapy.
Huang T; Song C; Zheng L; Xia L; Li Y; Zhou Y
Mol Cancer; 2019 Mar; 18(1):62. PubMed ID: 30925929
[TBL] [Abstract][Full Text] [Related]
8. Proteomics profiling identifies extracellular vesicles' cargo associated with tumour cell induced platelet aggregation.
McNamee N; de la Fuente LR; Santos-Martinez MJ; O'Driscoll L
BMC Cancer; 2022 Sep; 22(1):1023. PubMed ID: 36171564
[TBL] [Abstract][Full Text] [Related]
9. An extensive study of potential inhibitors of extracellular vesicles release in triple-negative breast cancer.
McNamee N; Catalano M; Mukhopadhya A; O'Driscoll L
BMC Cancer; 2023 Jul; 23(1):654. PubMed ID: 37442985
[TBL] [Abstract][Full Text] [Related]
10. N-Linked glycosylation profiles of therapeutic induced senescent (TIS) triple negative breast cancer cells (TNBC) and their extracellular vesicle (EV) progeny.
Kavanagh EL; Halasz M; Dowling P; Withers J; Lindsay S; Higgins MJ; Irwin JA; Rudd PM; Saldova R; McCann A
Mol Omics; 2021 Feb; 17(1):72-85. PubMed ID: 33325943
[TBL] [Abstract][Full Text] [Related]
11. Anticancer Therapy Targeting Cancer-Derived Extracellular Vesicles.
Cheng X; Henick BS; Cheng K
ACS Nano; 2024 Mar; 18(9):6748-6765. PubMed ID: 38393984
[TBL] [Abstract][Full Text] [Related]
12. The role of extracellular vesicles from different origin in the microenvironment of head and neck cancers.
Xie C; Ji N; Tang Z; Li J; Chen Q
Mol Cancer; 2019 Apr; 18(1):83. PubMed ID: 30954079
[TBL] [Abstract][Full Text] [Related]
13. Exosomes in triple negative breast cancer: From bench to bedside.
Tang W; Xia M; Liao Y; Fang Y; Wen G; Zhong J
Cancer Lett; 2022 Feb; 527():1-9. PubMed ID: 34902521
[TBL] [Abstract][Full Text] [Related]
14. Hypoxic regulation of extracellular vesicles: Implications for cancer therapy.
Yoo S; Choi S; Kim I; Kim IS
J Control Release; 2023 Nov; 363():201-220. PubMed ID: 37739015
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of Drug Resistance in Cancer: The Role of Extracellular Vesicles.
Samuel P; Fabbri M; Carter DRF
Proteomics; 2017 Dec; 17(23-24):. PubMed ID: 28941129
[TBL] [Abstract][Full Text] [Related]
16. Enrichment of circulating tumor-derived extracellular vesicles from human plasma.
Yoh KE; Lowe CJ; Mahajan S; Suttmann R; Nguy T; Reichelt M; Yang J; Melendez R; Li Y; Molinero L; Ruppel J; Xu W; Plaks V
J Immunol Methods; 2021 Mar; 490():112936. PubMed ID: 33242493
[TBL] [Abstract][Full Text] [Related]
17. Triple-Negative Breast Cancer EVs Modulate Growth and Migration of Normal Epithelial Lung Cells.
Leone I; Santoro J; Soricelli A; Febbraro A; Santoriello A; Carrese B
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892050
[TBL] [Abstract][Full Text] [Related]
18. The Role of Extracellular Vesicles in Mediating Resistance to Anticancer Therapies.
Maleki S; Jabalee J; Garnis C
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920605
[TBL] [Abstract][Full Text] [Related]
19. Triple negative breast cancer-derived small extracellular vesicles as modulator of biomechanics in target cells.
Senigagliesi B; Samperi G; Cefarin N; Gneo L; Petrosino S; Apollonio M; Caponnetto F; Sgarra R; Collavin L; Cesselli D; Casalis L; Parisse P
Nanomedicine; 2022 Aug; 44():102582. PubMed ID: 35817390
[TBL] [Abstract][Full Text] [Related]
20. The role of extracellular vesicles in mediating progression, metastasis and potential treatment of hepatocellular carcinoma.
Yang N; Li S; Li G; Zhang S; Tang X; Ni S; Jian X; Xu C; Zhu J; Lu M
Oncotarget; 2017 Jan; 8(2):3683-3695. PubMed ID: 27713136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
